Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Cash & Equivalents (2017 - 2025)

Inmune Bio (INMB) has disclosed Cash & Equivalents for 9 consecutive years, with $24.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 18.3% to $24.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.8 million through Dec 2025, up 18.3% year-over-year, with the annual reading at $24.8 million for FY2025, 18.3% up from the prior year.
  • Cash & Equivalents hit $24.8 million in Q4 2025 for Inmune Bio, down from $27.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $84.5 million in Q3 2021 to a low of $19.3 million in Q1 2025.
  • Historically, Cash & Equivalents has averaged $43.7 million across 5 years, with a median of $40.7 million in 2021.
  • Biggest five-year swings in Cash & Equivalents: soared 720.6% in 2021 and later plummeted 49.02% in 2024.
  • Year by year, Cash & Equivalents stood at $74.8 million in 2021, then plummeted by 30.29% to $52.2 million in 2022, then crashed by 31.26% to $35.8 million in 2023, then crashed by 41.64% to $20.9 million in 2024, then rose by 18.3% to $24.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for INMB at $24.8 million in Q4 2025, $27.7 million in Q3 2025, and $33.4 million in Q2 2025.